Aytu is in the Headlines with Exclusive EXXUA Deal and $14.4M Public Offering to Drive Growth in Depression Market Aytu BioPharma (NASDAQ: AYTU) made headlines today with two major announcements: the exclusive U.S. commercialization rights to EXXUA™ (gepirone), a first-in-

#AYTU is making waves with an exclusive U.S. licensing deal for Exxua® and a $14.4M public offering. The company is strategically advancing its position in the growing depression treatment market.
#AytuBioPharma
prismmarketview.com/aytu-is-in-t...